Tarpeyo — Medical Mutual

Primary Immunoglobulin A Nephropathy (IgAN), initial therapy

Initial criteria

Patient is ≥ 18 years of age
The diagnosis has been confirmed by biopsy
Patient is at high risk of disease progression, defined by meeting the following criteria (a and b):
a. Patient meets ONE of the following: i. Proteinuria > 0.5 g/day; OR ii. Urine protein-to-creatinine ratio ≥ 0.8g/g
b. Patient has been receiving the maximum or maximally tolerated dose of ONE of the following for ≥ 90 days: i. Angiotensin converting enzyme inhibitor (ACEi); or ii. Angiotensin receptor blocker (ARB)
According to the prescriber, the patient has received ≥ 90 days of optimized supportive care, including blood pressure management, lifestyle modification, and cardiovascular risk modification
Patient has an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2
Patient has not previously been treated with Tarpeyo
The medication is prescribed by or in consultation with a nephrologist

10 months